New study aims to boost safety of targeted radiation cancer treatment

NCT ID NCT07389512

First seen Feb 05, 2026 · Last updated Jun 17, 2026 · Updated 14 times

Summary

This study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroendocrine tumors. Researchers will compare the number of medication changes suggested by pharmacists when they do a full medication review versus when they only check medical records.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CGFL Dijon

    NOT_YET_RECRUITING

    Dijon, 21000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Hospitalier Universitaire de Lille

    NOT_YET_RECRUITING

    Lille, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospices Civils de Lyon

    RECRUITING

    Bron, 69677, France

Conditions

The condition(s) this trial relates to.

cancer carcinoid tumor metastatic prostate carcinoma neoplasm neuroendocrine neoplasm prostate cancer thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.